Guidance
Evidence-based recommendations on Spectra Optia for automated red blood cell exchange in people with sickle cell disease.
Implementation
NICE has developed tools, in association with relevant stakeholders, to help organisations put this guidance into practice.
Is this guidance up to date?
We reviewed the evidence in August 2020. We found nothing new that affects the recommendations in this guidance.
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.
Guidance development process
How we develop NICE medical technologies guidance
NICE medical technologies guidance addresses specific technologies notified to NICE by sponsors. The ‘case for adoption’ is based on the claimed advantages of introducing the specific technology compared with current management of the condition. This case is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.
Clinical coding recommendations
Coding relevant to this guidance
SNOMED CT
Procedure
1065641000000100 | Automated red blood cell exchange transfusion (procedure)
Device
13031901000001105 | Spectra Optia centrifugation apheresis system (Terumo BCT) (physical object)
This guidance was previously called Spectra Optia for automatic red blood cell exchange in patients with sickle cell disease.